VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.00 price target on the stock.

VNRX has been the topic of a number of other research reports. StockNews.com began coverage on shares of VolitionRx in a research note on Tuesday, April 29th. They set a "sell" rating on the stock. HC Wainwright began coverage on VolitionRx in a research report on Tuesday, April 8th. They set a "buy" rating and a $2.50 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $3.33.

VolitionRx Price Performance

VolitionRx stock traded up $0.03 during trading hours on Wednesday, reaching $0.50. The stock had a trading volume of 170,166 shares, compared to its average volume of 175,858. The company has a fifty day simple moving average of $0.53 and a 200-day simple moving average of $0.60. VolitionRx has a 52 week low of $0.42 and a 52 week high of $0.90. The stock has a market cap of $50.69 million, a PE ratio of -1.39 and a beta of 1.00.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds purchased 181,818 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief executive officer now owns 2,299,222 shares of the company's stock, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VNRX. Two Sigma Securities LLC purchased a new stake in VolitionRx in the 4th quarter worth approximately $29,000. Millennium Management LLC bought a new position in shares of VolitionRx in the fourth quarter worth approximately $36,000. Northern Trust Corp increased its stake in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after purchasing an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. raised its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the period. Institutional investors own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.